Antitumor Activity of the Investigational Proteasome Inhibitor MLN9708 in Mouse Models of B-cell and Plasma Cell Malignancies

PURPOSE: The clinical success of the first-in-class proteasome inhibitor bortezomib (VELCADE) has validated the proteasome as a therapeutic target for treating human cancers. MLN9708 is an investigational proteasome inhibitor that, compared with bortezomib, has improved pharmacokinetics, pharmacodyn...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Lee, Edmund C., Fitzgerald, Michael, Bannerman, Bret, Donelan, Jill, Bano, Kristen, Terkelsen, Jennifer, Bradley, Daniel P., Subakan, Ozlem, Silva, Matthew D., Liu, Ray, Pickard, Michael, Li, Zhi, Tayber, Olga, Li, Ping, Hales, Paul, Carsillo, Mary, Neppalli, Vishala T., Berger, Allison J., Kupperman, Erik, Manfredi, Mark, Bolen, Joseph B., Van Ness, Brian, Janz, Siegfried
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2011
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3443972/
https://ncbi.nlm.nih.gov/pubmed/21903769
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-11-0636
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak